Detection of Retroviruses and HIV-1 Groups -M and -O Discrimination within Clinical Serum Samples
CDC researchers have developed methods for detecting retroviruses within a patient blood sample and discriminating HIV-1 samples within serum specimens. HIV-1 can be genetically classified into two major groups, group M (major) and Group O (outlier) with group O comprising all divergent viruses that do not cluster with group M. The identification of group O infections raised public health concerns about the safety of the blood supply because HIV-1 screening by group M-based serologic tests does not consistently detect group O infection.
The assay is based on the selective inhibition of Amp-RT reactivity of Group M viruses by nevirapine, a non-nucleoside RT inhibitor. Group O viruses can be generically identified by the resistance of their Amp-RT activity to nevirapine. The assay can be used to screening of the blood supply and to rapidly differentiate group M from group O virus.
Potential Commercial Applications: | Competitive Advantages: |
|
|
Development Stage:
In vitro data available
Related Invention(s):
E-129-2013-0
E-129-2013-1
Inventors:
Walid Heneine (CDC) ➽ more inventions...
Thomas Folks (CDC) ➽ more inventions...
Shinji Yamamoto (CDC) ➽ more inventions...
William Switzer (CDC) ➽ more inventions...
Intellectual Property:
U.S. Pat: 5,849,494 issued 1998-12-15
U.S. Pat: 6,136,534 issued 2000-10-24
US Application No. 09/123,012
US Application No. 08/379,851
Various international patents issued or pending
Publications:
Yamamoto S, et al. PMID 8882946
Heneine W, et al. PMID 7538549
Reisler RB, et al. PMID 11176273
Licensing Contact:
Admin. Licensing Specialist (ALS),
Email:
Phone:
OTT Reference No: E-232-1993-0
Updated: Jan 27, 2014